# OnCo record paper-paez-egfr-mutations-gefitinib-science-2004 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-paez-egfr-mutations-gefitinib-science-2004" ;
  schema:name "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy"@en ;
  schema:description "The second of the two 2004 papers that found EGFR mutations. It also explained why Japanese patients responded to gefitinib far more often than American ones: the mutation was simply much more common in Japan."@en ;
  schema:url <https://onco.cc/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1126/science.1099314>, <https://pubmed.ncbi.nlm.nih.gov/15118125/> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1126/science.1099314> ;
  schema:datePublished "2004"^^xsd:gYear ;
  schema:author "Paez JG, Jänne PA, Lee JC, et al." ;
  onco:related <https://onco.cc/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/>, <https://onco.cc/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/>, <https://onco.cc/roadmaps/targeted-therapy-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/lung-adenocarcinoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/terms/ngs/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/gefitinib/> ;
  onco:institutions <https://onco.cc/institutions/dana-farber/>, <https://onco.cc/institutions/broad-institute/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/oncogene-addiction/> ;
  onco:people <https://onco.cc/people/pasi-janne/>, <https://onco.cc/people/matthew-meyerson/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-trial-diversity/> ;
  onco:journals <https://onco.cc/journals/science/> .
